Ascella Biosystems, Inc. announced that it will receive a seed round of funding on April 22, 2021. The company entered into an agreement with new investor Axel Mark Inc. (TSE:3624). The transaction will include participation from new investor Axel Mark Inc. (TSE:3624) and other investors. The transaction is expected to close during April 2021. The company will issue convertible notes in the transaction. The transaction has been approved by the board of directors of the investor.